腺病毒介导的血管内皮生长因子联合干细胞生长因子治疗严重肢体缺血的实验研究

doi:10.3969/j.issn.1006-5725.2024.05.009

Abstract

Abstract:

Objective To explore the role and efficacy of VEGF and HGF gene adenovirus vector in promoting angiogenesis in ischemic tissue. Methods 84 Kunming mice were randomly divided into sham group， control group， VEGF group， HGF group and VEGF+HGF group， and the left lower limb ischemia model was established. The blood supply of ischemic tissue was observed by rheometer， and the expression levels of VEGF and HGF in each group were detected by Western Blot and ELISA. Immunohistochemical staining was used to detect angiogenesis （CD31， SMA） in ischemic tissues. Safety was assessed by side effects during treatment in mice. Results After the successful modeling， the blood flow velocity of the left lower limb in each group decreased significantly. On the 7th day after operation， the blood flow of the left lower limb in each group was significantly better than that on the 0th day after operation （P < 0.05）， and the blood flow of the left lower limb in Ad-VEGF-HGF group was significantly better than that in other groups （P < 0.05）. On the 28th day after operation， the blood flow of the left lower limb in Ad-VEGF-HGF group gradually stabilized， the blood flow in Ad-VEGF-HGF group was significantly better than that in other groups， and both VEGF group and HGF group were significantly better than the control group （P < 0.05）. On the 7th， 14th， and 28th days following surgery， HGF and VEGF protein levels in the Ad-HGF， Ad-VEGF， and Ad-VEGF-HGF groups were substantially greater than those in the control group （P < 0.05）. The expression level in the Ad-VEGF-HGF group peaked on the 14th day （all P < 0.001） and subsequently declined to preoperative levels on the 28th day after operation. Conclusion Ad-VEGF-HGF gene injection can effectively boost VEGF and HGF protein expression and rapidly reach the relative peak level， encouraging angiogenesis after lower limb ischemia， increasing blood flow， and improving lower limb circulation.

Key words: vascular endothelial growth factor, stem cell growth factor, lower limb ischemia, adenovirus vector

CLC Number:

R543.5

Rui ZHONG,Jianing WANG,Lei ZHANG,Lingyun GUO,Jianye YANG,Fei ZHENG,Yuwen YAN,Danli YU,Liguo. TAN. Experimental study on treatment of severe limb ischemia with Ad⁃hVEGF⁃hHGF gene[J]. The Journal of Practical Medicine, 2024, 40(5): 639-645.

Figures/Tables 9

Tab.1

Fig.1

Fig.2

Fig.3

Fig.4

Tab.2

Fig.5

Fig.6

Fig.7

References 26

1	王书凡，赫玉香，程小龙，等. 杜鹃花总黄酮通过激活大鼠脑基底动脉血管内皮细胞TRPV4、Kca3.1和Kca2.3通道改善缺血性脑损伤［J］. 皖南医学院学报，2020，39（6）：516-520. doi:10.3969/j.issn.1002-0217.2020.06.002 doi: 10.3969/j.issn.1002-0217.2020.06.002
2	王爱红，石鸿雁，许樟荣. 基于临床症状和体征评估糖尿病足溃疡肢体缺血严重程度的价值［J］. 中华糖尿病杂志，2020，12（8）：585-588. doi:10.3760/cma.j.cn115791-20200506-00268 doi: 10.3760/cma.j.cn115791-20200506-00268
3	梁永红，冯超，梁顺添，等. 血管腔内介入治疗下肢严重缺血后急性肾损伤危险因素［J］. 中国介入影像与治疗学，2021，18（2）：91-94.
4	REIS P E， DE CARVALHO L P， YASUMURA E， et al. Impact of angiogenic therapy in the treatment of critical lower limb ischemia in an animal model［J］. Vasc Endovascular Surg， 2014，48（3）：207-216. doi:10.1177/1538574413518119 doi: 10.1177/1538574413518119
5	李志娟，庄百溪，马鲁波. 慢性威胁肢体性缺血中医药介入治疗研究进展［J］. 中西医结合心脑血管病杂志，2021，19（6）：956-958. doi:10.12102/j.issn.1672-1349.2021.06.016 doi: 10.12102/j.issn.1672-1349.2021.06.016
6	血管外科学会、欧洲血管外科学会和世界血管学会联盟全球血管指南编写小组. 慢性肢体威胁性缺血治疗的全球血管指南（全译）［J］. 中华血管外科杂志，2021，6（Z1）：1-108，F3.
7	杨川，郭发才，周栋. 重症下肢缺血治疗的研究进展［J］.重庆医学，2015，44（4）：544-547.
8	WATANABE M， NISHIKAWAJI Y， KAWAKAMI H， et al. Adenovirus biology，recombinant adenovirus，and adenovirus usage in gene therapy［J］.Viruses，2021，13（12）：2502. doi:10.3390/v13122502 doi: 10.3390/v13122502
9	SAKURAI F， TACHIBANA M， MIZUGUCHI H. Adenovirus vector-based vaccine for infectious diseases［J］. Drug Metab Pharmacokinet， 2022，42：100432. doi:10.1016/j.dmpk.2021.100432 doi: 10.1016/j.dmpk.2021.100432
10	杨宇，董继红，张荣荣，等. 年龄相关性黄斑变性患者抗VEGF治疗视力预后的影响因素研究［J］. 皖南医学院学报，2022，41（1）：36-39. doi:10.3969/j.issn.1002-0217.2022.01.010 doi: 10.3969/j.issn.1002-0217.2022.01.010
11	OZGUIR E， HEIDENREICH A， DAGTEKIN O， et al. Distribution of EphB4 and EphrinB2 in normal and malignant urogenitaltissue［J］. Urol Oncol，2011，29（ 1）：78-84. doi:10.1016/j.urolonc.2008.12.020 doi: 10.1016/j.urolonc.2008.12.020
12	VIJAYAKUMAR A， TIWARI R， KUMAR PRABHUSWAMY V.Throm-boangiitis obliterans （Buerger' s disease）-current practices［J］. Int J Inflam，2013，20（13）：1569.
13	SHIGEMATSU H， YASUDA K， IWAI T， et al. Randomized，double-blind， placebo-controlled clinical trial of hepato-cyte growth factor plasmid for critical limb ischemia［J］. Gene Ther，2010，17（9）：1152-1161. doi:10.1038/gt.2010.51 doi: 10.1038/gt.2010.51
14	MORISHITA R， MAKINO H， AOKI M，et al. Phase I/IIa clinicaltrial of therapeutic angiogenesis using hepatocyte growthfactor gene transfer to treat critical limb ischemia［J］. Arterioscler Throm Vas Biol， 2011，31（3）：713-720. doi:10.1161/atvbaha.110.219550 doi: 10.1161/atvbaha.110.219550
15	FARBER A， EBERHARDT R T. The current state of critical limb ischemia： a systematic review［J］. JAMA Surg， 2016， 151（11）： 1070-1077. doi:10.1001/jamasurg.2016.2018 doi: 10.1001/jamasurg.2016.2018
16	FARD B， DIJKSTRA P U， NEDA Study Group， et al. Mortality， reamputation， and preoperative comorbidities in patients undergoing dysvascular lower limb amputation［J］. Ann Vasc Surg， 2020， 64： 228-238. doi:10.1016/j.avsg.2019.09.010 doi: 10.1016/j.avsg.2019.09.010
17	FABIANI I， CALOGERO E， PUGLIESE N R， et al. Critical limb ischemia： a practical up-to-date review［J］. Angiology， 2018， 69（6）： 465-474. doi:10.1177/0003319717739387 doi: 10.1177/0003319717739387
18	HAGHIGHAT L， IONESCU C N， REGAN C J， et al. Review of the current basic science strategies to treat critical limb ischemia［J］. Vasc Endovascular Surg， 2019， 53（4）： 316-324. doi:10.1177/1538574419831489 doi: 10.1177/1538574419831489
19	郭平凡. 下肢慢性缺血性疾病的诊治［J］. 中国血管外科杂志（电子版），2021，13（4）：299-301，305.
20	JOHNSON T， ZHAO L， MANUEL G， et al. Approaches to therapeutic angiogenesis for ischemic heart disease［J］. J Mol Med， 2019， 97（2）： 141-151. doi:10.1007/s00109-018-1729-3 doi: 10.1007/s00109-018-1729-3
21	YLÄ-HERTTUALA S. Gene therapy of critical limb ischemia enters clinical use［J］. Mol Ther， 2019， 27（12）： 2053. doi:10.1016/j.ymthe.2019.11.001 doi: 10.1016/j.ymthe.2019.11.001
22	MÄKINEN K， MANNINEN H， HEDMAN M， et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery： a randomized， placebo-controlled， double-blinded phase Ⅱ study［J］. Mol Ther， 2002， 6（1）： 127-133. doi:10.1006/mthe.2002.0638 doi: 10.1006/mthe.2002.0638
23	BARĆ P， ANTKIEWICZ M， ŚLIWA B， et al. Double VEGF/HGF gene therapy in critical limb ischemia complicated by diabetes mellitus［J］. J Cardiovasc Transl Res， 2021，14： 409-415. doi:10.1007/s12265-020-10066-9 doi: 10.1007/s12265-020-10066-9
24	李存娣，曹伟娅，王健. 血管内皮生长因子受体与肝细胞癌侵袭转移的关系［J］. 临床肝胆病杂志，2019，35（7）：1616-1620. doi:10.3969/j.issn.1001-5256.2019.07.042 doi: 10.3969/j.issn.1001-5256.2019.07.042
25	RIAUD M， HILAIRET G， SINDJI L， et al. Pharmacology active microcarriers delivering HGF associated with extracellular vesicles for myocardial repair［J］. Eur J Pharm Biopharm， 2021， 169： 268-279. doi:10.1016/j.ejpb.2021.10.018 doi: 10.1016/j.ejpb.2021.10.018
26	ROSENGART T K， LEE L Y， PATEL S R， et al.Angiogenesis Gene Therapy Phase IAssessment of Direct Intramyocardial Administration of an Adenovirus VectorExpressing VEGF12i cDNA to Individuals With Clinically Significant SevereCoronary Artery Disease［J］. Circulation， 1999，100：468-474. doi:10.1161/01.cir.100.5.468 doi: 10.1161/01.cir.100.5.468

时间	术前	术后即刻	术后第7天	术后第14天	术后第28天
空白对照组	1.03 ± 0.98^#	0.47 ± 0.40	0.67 ± 0.61^#	0.79 ± 0.74^#	0.82 ± 0.76^#
VEGF	1.05 ± 1.03^#	0.40 ± 0.36	0.69 ± 0.68^#	0.89 ± 0.85^#	0.89 ± 0.85^#
HGF	0.99 ± 0.97^#	0.36 ± 0.34	0.65 ± 0.63^#	0.85 ± 0.83^#	0.86 ± 0.82^#
VEGF+HGF	1.02 ± 0.98^#	0.42 ± 0.40	0.80 ± 0.77^#*△▲	0.99 ± 0.95^#*	0.97 ± 0.93^#*

指标	术前	术后第7天	术后第14天	术后第28天	F值	P值
VEGF	34.24 ± 1.05^#	36.99 ± 9.80^#	88.79 ± 23.22	23.98 ± 0.46^#	83.86	< 0.001
HGF	1.89 ± 0.80^#	5.19 ± 1.75^#	7.26 ± 0.38	4.20 ± 0.73^#	14.01	< 0.001

[1]	Canwei CHEN,Zhuangwen LIAO,Ziwen FAN,Shuai HUANG,Yan HUANG,Binwei CHEN. LAMP3 inhibited the proliferation， metastatic and PC⁃3⁃induced vasculogenesis of HUVEC by regulating VEGF/AKT signaling [J]. The Journal of Practical Medicine, 2024, 40(2): 182-187.
[2]	Yaoxin CHEN,Songbo LI,Guanjun FANG,Guobiao YE,Xianyin. LIU. Analysis of the relationship between FGF⁃1 and VEGF expression in the ligamentum flavum of patients with lumbar spinal stenosis and restenosis after decompression [J]. The Journal of Practical Medicine, 2023, 39(18): 2289-2293.
[3]	WU Yuliang, WU Chunling, WU Dan. . The correlation of endometriosis with serum levels of FLT1 and CTRP3 [J]. The Journal of Practical Medicine, 2023, 39(14): 1798-1803.
[4]	HUANG Jianmin, YUN Yanfang, YANG Guixin, CHEN Haiyan, JIANG Yongming, HUANG Dongxu, LIU Jie, MO Xiaorong, LI Xuebin.. Effects of survivin inhibitor YM155 on microvessel density and angiogenesis⁃related gene expression in rats with cerebral infarction [J]. The Journal of Practical Medicine, 2022, 38(8): 946-951.
[5]	LI Jihong, NIU Mengqi.. Predictive value of vascular endothelial growth factor level in patients with type 2 diabetes mellitus compli⁃ cated with retinal microangiopathy [J]. The Journal of Practical Medicine, 2022, 38(8): 1001-1005.
[6]	LIU Yang, HE Chunshui, ZHANG Lifeng, ZENG Wei, LIN Yao, GENG Caijuan, WANG Ke, WANG Qiqi, HUANG Wei, WEI Haijun.. Clinical efficacy of AngioJet⁃assisted mechanical thrombectomy for the treatment of acute lower limb isch⁃ emia and its prognosis [J]. The Journal of Practical Medicine, 2022, 38(10): 1255-1259.
[7]	XIA Xu, CUI Hongquan, HU Peisen, WANG Jiaotuo.. Role of rehmannia glutinosa polysaccharide in proliferation and apoptosis of prostate cancer PC ⁃ 3 cells and effect of rehmannia polysaccharide on VEGF/Akt signaling pathway [J]. The Journal of Practical Medicine, 2021, 37(17): 2194-2198.
[8]	LIU Meilian, SU Faming, LI Xiaoling, PENG Xiaoxia, CHEN Xiaoming. . R736.1 Research on the predictive value of VEGF and Ang⁃2 in thyroid papillary carcinoma and its concomitant cervical lymph node metastasis [J]. The Journal of Practical Medicine, 2021, 37(11): 1441-1444.

Experimental study on treatment of severe limb ischemia with Ad⁃hVEGF⁃hHGF gene

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 9

References 26

Related Articles 8

Recommended Articles

Metrics

Comments